Pre-made Zansecimab benchmark antibody ( Whole mAb, anti-ANGPT2 therapeutic antibody, Anti-AGPT2/ANG2/LMPHM10 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-641
Pre-Made Zansecimab biosimilar, Whole mAb, Anti-ANGPT2 Antibody: Anti-AGPT2/ANG2/LMPHM10 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Zansecimab (formerly LY 3127804) is a selective monoclonal antibody against angiopoietin 2 (Ang2), being developed by Eli Lilly and Company, for the treatment of solid tumours including gastric cancer and hepatocellular carcinoma (HCC) and COVID-19 pneumonia.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Zansecimab biosimilar, Whole mAb, Anti-ANGPT2 Antibody: Anti-AGPT2/ANG2/LMPHM10 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Solid tumours|